Treatment of Low Libido in a 44-Year-Old Perimenopausal Woman
For a 44-year-old perimenopausal woman with low libido, testosterone replacement therapy can be considered as a treatment option after comprehensive biopsychosocial assessment, though the evidence is strongest for postmenopausal women with hypoactive sexual desire disorder (HSDD). 1
Understanding the Clinical Context
Your patient is in perimenopause, which represents a transitional phase where the evidence base is less robust than for postmenopausal women. The 2014 Endocrine Society guideline specifically addresses postmenopausal women, noting that transdermal testosterone at 300 µg/day significantly improved satisfying sexual events (from 3 to 5 per month), with improvements in arousal, pleasure, orgasm, and reduced personal distress in both surgically and naturally menopausal women 1. However, limited data also support use in late reproductive age premenopausal women 2.
Key Diagnostic Considerations Before Treatment
Before considering testosterone therapy, you must:
- Rule out modifiable factors: relationship problems, mental health disorders (depression, anxiety), medications (SSRIs, oral contraceptives, oral estrogen), chronic medical conditions, and inadequate estrogen replacement if already on hormone therapy 1, 3
- Confirm this is HSDD: persistent low desire causing personal distress, not simply age-related changes in sexual frequency 1, 3
- Assess for contraindications: hormone-sensitive breast cancer (relative contraindication), untreated cardiovascular risk factors 4, 3
Treatment Algorithm
First-Line Approach: Address Underlying Factors
- Optimize estrogen status: If she has vasomotor symptoms or other menopausal symptoms, ensure adequate estrogen replacement first, as testosterone works best with adequate estrogen 1, 4
- Review medications: Oral estrogen increases SHBG and may worsen androgen deficiency; consider transdermal estrogen instead 1
- Biopsychosocial assessment: Address relationship issues, stress, body image concerns through counseling 3, 5
Second-Line: Testosterone Therapy
If low libido persists despite adequate estrogen replacement and addressing modifiable factors, testosterone therapy is reasonable 1, 3, 2.
Testosterone Replacement: Specific Recommendations
Baseline Testing
- Measure total testosterone (though not for diagnosis of HSDD, but for monitoring) 3, 2
- Do NOT use testosterone levels to diagnose HSDD - this is a clinical diagnosis based on symptoms and distress 1, 3, 2
- Screen for cardiovascular risk factors, lipid profile 5
Available Modalities (Critical Limitation)
There are NO FDA-approved testosterone formulations for women in the United States 3, 6, 2, 7. This creates a significant treatment gap. Your options are:
1. Transdermal Testosterone (Preferred Route)
- Dosing: Aim for physiologic premenopausal levels - approximately 300 µg/day transdermal 1
- Formulation: Use male testosterone gel at 1/10th the male dose 3, 8
- Example: Male gel 1.62% delivers 20.25 mg per pump actuation 9
- For women: Use approximately 1/10th of male dose to achieve ~300 µg/day
- Application: Upper arms/shoulders, covered by clothing after drying 9
- Evidence: This is the best-studied formulation with moderate-to-high quality evidence for efficacy 1
2. Testosterone Cream (Compounded)
- Caution: Compounded products lack standardized quality control and cannot be routinely recommended unless approved products unavailable 3, 2
- If used, must be from pharmacy compliant with Good Manufacturing Practice 3
- Recent pilot data showed improvements in mood and cognition with testosterone cream/gel in perimenopausal women 10
3. Subcutaneous Testosterone Implants
- Available in some countries (UK, Australia) but not widely in US 4
- Risk: Often deliver supraphysiologic levels and are NOT recommended 3
- Should be limited to 24 months if used 4
4. NOT Recommended
- Testosterone pellets/injections: Result in supraphysiologic levels 3
- Oral methyltestosterone: Potential liver toxicity, less favorable safety profile 11
- DHEA: Insufficient evidence for benefit in sexual function 1
Monitoring Protocol
Critical monitoring steps 3, 2:
- Baseline: Total testosterone level, clinical assessment
- 3-6 weeks: Repeat testosterone level to ensure physiologic premenopausal range (approximately 300-500 ng/dL total testosterone)
- Every 6 months:
- Testosterone level (maintain in physiologic range)
- Assess for androgen excess: acne, hirsutism, voice changes, clitoromegaly
- Clinical response assessment
- If no benefit by 6 months: Discontinue therapy 3
Expected Outcomes
Based on the strongest evidence 1:
- Modest improvement: Increase of approximately 1-2 satisfying sexual events per month
- Improvement in multiple domains: desire, arousal, orgasm, reduced distress
- Placebo response is substantial: 40-48% reduction in distress with placebo alone
- Effect size is moderate: Not a dramatic transformation
Safety Considerations
Short-term safety (up to 24 months) 1, 3:
- No increased breast cancer risk with physiologic doses
- No serious cardiovascular events in trials
- Androgenic side effects (acne, hirsutism) are mild and reversible
- However: Long-term safety data beyond 24 months are lacking 1, 3
Special concern for your perimenopausal patient 4:
- Data are primarily from postmenopausal women
- Impact on breast cancer risk in premenopausal/perimenopausal women is unknown
- Should be used with caution and informed consent about limited data in this age group
Critical Pitfalls to Avoid
- Using testosterone without adequate estrogen: Testosterone works best with concurrent estrogen therapy 1
- Supraphysiologic dosing: Using male doses or pellets leads to excessive levels and side effects 3
- Diagnosing based on testosterone levels: HSDD is a clinical diagnosis; low testosterone levels do NOT define the condition 1, 3, 2
- Ignoring psychosocial factors: Testosterone alone without addressing relationship/psychological issues is insufficient 3, 5
- Inadequate monitoring: Must check levels to avoid supraphysiologic dosing 3, 2
- Secondary exposure risk: Warn about transfer to children/partners from application sites 9
Practical Implementation
Informed consent discussion must include 3, 6, 2:
- Off-label use (no FDA-approved formulation for women)
- Modest expected benefit (1-2 additional satisfying events/month)
- Unknown long-term safety beyond 2 years
- Need for ongoing monitoring
- Androgenic side effects
- Cost (often not covered by insurance for this indication)
- Start transdermal testosterone at physiologic dose
- Reassess at 3-6 months
- If no improvement by 6 months, discontinue
- If beneficial, continue with 6-month monitoring
- Consider limiting duration to 24 months given lack of long-term data
Alternative/Adjunctive Options
If testosterone is not appropriate or desired 5:
- Psychosexual therapy: Cognitive-behavioral approaches for HSDD
- Optimize general health: Exercise, sleep, stress management
- Address vasomotor symptoms: May improve overall quality of life and indirectly affect libido
- Vaginal estrogen: If genitourinary symptoms contribute to sexual dysfunction
The evidence supports cautious use of transdermal testosterone in your perimenopausal patient with persistent HSDD after addressing modifiable factors, using off-label male formulations at 1/10th the dose, with close monitoring and informed consent about limited long-term safety data in this population 1, 3, 2.